# A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

> **NCT07710196** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Nacuity Pharmaceuticals, Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Retinitis Pigmentosa (RP)
- Usher Syndrome

## Interventions

- **DRUG:** Placebo
- **DRUG:** NPI-001

## Key facts

- **NCT ID:** NCT07710196
- **Lead sponsor:** Nacuity Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2029-02
- **Final completion:** 2029-02
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07710196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07710196, "A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07710196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*